Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

This article was originally published here

The randomized, open label, multi-center study will enroll up to 100 non-hospitalized patients who have a positive SARS-CoV-2 test and are symptomatic to assess the antiviral activity, safety,

The post Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply